With these trends in view, let’s look at the 7 most undervalued biotech stocks to invest in.

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors�reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Provide specific products and services to you, such as portfolio management or data aggregation. Develop and improve features of our offerings. Gear advertisements and other marketing efforts ...

The 10 most undervalued stocks from our Best Companies to Own list as of Feb. 27, 2025, were: Here’s a little bit about why ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

In this article, in addition to analyzing GSK's financial results for Q4 2024, I also presented an analysis of the most interesting developments in its portfolio. However, that's not all.

Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the game of "volume" in the market. This large portfolio also gives ...

UK drugmaker GSK is struggling to convince the market ... for GSK is to persuade investors it can rebuild its oncology portfolio, after leaving the market in 2015. It subsequently went back ...

SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...